Verition Fund Management
RNAM

Verition Fund Management’s Avidity Biosciences RNAM Stock Holding History

Verition Fund Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-680,721
Closed -$49.1M – 3333
2025
Q4 		$49.1M Buy
680,721
+644,894
+1,800% +$41.7M 0.19% 66
2025
Q3 		$1.56M Buy
35,827
+4,460
+14% +$180K 0.01% 2172
2025
Q2 		$891K Buy
31,367
+21,900
+231% +$653K ﹤0.01% 2560
2025
Q1 		$279K Sell
9,467
-77,635
-89% -$2.42M ﹤0.01% 2893
2024
Q4 		$2.53M Buy
87,102
+66,686
+327% +$2.79M 0.01% 1401
2024
Q3 		$938K Buy
20,416
+13,011
+176% +$565K ﹤0.01% 1929
2024
Q2 		$302K Buy
+7,405
New +$212K ﹤0.01% 2343
2023
Q3 		– Sell
-30,460
Closed -$338K – 2636
2023
Q2 		$338K Buy
+30,460
New +$382K ﹤0.01% 1477

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Verition Fund Management's RNAM Position: Q1 2026 in Review

Verition Fund Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 680,721 shares — an estimated $49.1M sold.

Verition Fund Management first reported a position in RNAM in Q2 2023 and held it in 8 quarters. The position peaked at $49.1M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Verition Fund Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 680,721 Avidity Biosciences shares in Q1 2026, an estimated $49.1M.
  • Verition Fund Management first reported a position in Avidity Biosciences in Q2 2023 and held it in 8 quarters.
  • Verition Fund Management's Avidity Biosciences position peaked at $49.1M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.